Novo Nordisk to build new corporate centre in Bagsværd, Denmark

Novo NordiskNovo Nordisk is investing around 1 billion Danish kroner (134 million euros) in two new office buildings with surrounding green space in Bagsværd, Denmark. The project is expected to create more than 300 jobs during the construction phase. The new office premises will house Novo Nordisk's top management, 1,100 administrative employees and a number of shared facilities. Groundbreaking will take place in October, and the new corporate centre is expected to be ready for occupancy at the end of 2013.

With the new premises, Novo Nordisk will be consolidating a number of administrative functions currently scattered across Greater Copenhagen. In future, the employees will be gathered at new, contemporary offices at the Bagsværd and Søborg sites.

"Although Novo Nordisk is primarily set to grow outside of Denmark in the coming years, we are looking forward to consolidating the administrative functions in Bagsværd, where we have been present since the 1950s. The new buildings will give our employees the best conditions for interacting across functional divides and with our colleagues abroad," says Lars Rebien Sørensen, president and CEO of Novo Nordisk.

The insulin molecule with its contoured spiral shape was a key source of inspiration for Henning Larsen Architects. The new building will be distinctive in its white materials combined with Nordic stone and woods. The aim is to create a dynamic and inspiring work setting closely allied with external natural features, in an elegant, streamlined and efficient centre for Novo Nordisk.

Around 14,000 of Novo Nordisk's 32,000 employees work in Denmark. Beyond the Copenhagen area, Novo Nordisk has activities in Kalundborg, Hillerød, Værløse, Måløv and Hjørring.

About the building project

  • The new corporate centre will consist of two office buildings - a circular, six-storey building and a lower, four-storey building, underground parking and a large planted landscape.
  • Situated on a 37,000 m2 site, the new buildings will take up an area of 8,800 m2 with a total floorage of 50,500 m2.
  • The buildings will feature low energy consumption with the aid of sensors, light and ventilation, and will meet the 2015 energy requirements for new buildings.

Most Popular Now

Novartis rises to second place in 2018 Access to M…

Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to ...

MSD is looking for a digital health solution to em…

MSD Lebanon is looking for an external partner to co-create a digital solution that helps oncologists to stay updated with relevant clinical content about cancer. The sol...

Lilly submits New Drug Application to the FDA for …

Eli Lilly and Company (NYSE: LLY) has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lasmiditan for the acute...

FDA approves new treatment for patients with acute…

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for t...

Sanofi builds focus on rare blood disorders and ca…

Some of the most serious unmet patient needs today are in the field of hematology. Rare blood disorders and blood-related cancers continue to be a major focus of research...

New study reveals probiotics do not help children …

Probiotics are a multibillion-dollar industry with marketing claims of being an effective treatment for a multitude of ailments, including diarrhea. However, findings fro...

Merck and Pfizer provide update on avelumab in pla…

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxor...

Bristol-Myers Squibb awards "Golden Tickets…

Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today anno...

U.S. FDA approves Larotrectinib, the first TRK inh…

The U.S. Food and Drug Administration (FDA) has approved larotrectinib, the first oral TRK inhibitor, under the brand name Vitrakvi®. The approval is for the treatment of...

Scorpion venom to shuttle drugs into the brain

The Peptides and Proteins lab at the Institute for Research in Biomedicine (IRB Barcelona) has published a paper in Chemical Communications describing the capacity of a s...

Abbott recommends rejection of below-market mini-T…

Abbott (NYSE: ABT) received notice of an unsolicited mini-tender offer by Baker Mills LLC (Baker Mills) to purchase up to 60,000 Abbott common shares, representing approx...

AstraZeneca to divest US Synagis rights to Sobi

AstraZeneca has agreed to sell US rights to Synagis (palivizumab) used for the prevention of serious lower respiratory tract infection (LRTI) caused by respiratory syncyt...